Concepedia

Michael S. van der Veer

MS

3

Publications

1.3K

Citations

3

H-Index

2010

Active since

Affiliations

University Medical Center Utrecht(Current)

Genmab (Netherlands)

Utrecht University

Meander Medisch Centrum

Michael S. van der Veer is an author at University Medical Center Utrecht specializing in radiation oncology, cancer research, and tumor microenvironment.

Top concepts

Publications per year

2010–2011

3

Publications

3

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

Michel de Weers, Yu‐Tzu Tai, Michael S. van der Veer et al. · The Journal of Immunology · 2010 · 996 citations · Full text

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

Michael S. van der Veer, Michel de Weers, Berris van Kessel et al. · Haematologica · 2010 · 216 citations · Full text

The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies

Michael S. van der Veer, Michel de Weers, Berris van Kessel et al. · Blood Cancer Journal · 2011 · 98 citations · Full text

, , +14

Rows per page

1–3 of 3